Nubeqa® (darolutamide) – Expanded indication
August 5, 2022 - The FDA announced the approval of Bayer’s Nubeqa (darolutamide), for the treatment of adult patients with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with docetaxel.
Download PDF
